Showing results (231-240 of 648) with videos related to

Sort By:
Pageof 65
Hemasphere|February 20, 2020
Risk and Response Adapted Treatment Guidelines for Managing First Relapsed and Refractory Classical Hodgkin Lymphoma in Children and Young People. Recommendations from the EuroNet Pediatric Hodgkin Lymphoma GroupStephen Daw, Dirk Hasenclever, Maurizio Mascarin, et al.
Hemasphere|February 20, 2020
Factor VIII Fc Fusion Protein but not FVIII Drives Human Monocyte-Derived Dendritic Cell Activation via FcγRIIaChristoph Kannicht, Ilona Danßmann, Constanze Weilandt, et al.
Hemasphere|March 20, 2019
Increased Red Cell KCNN4 Activity in Sporadic Hereditary Xerocytosis Associated With Enhanced Single Channel Pressure Sensitivity of PIEZO1 Mutant V598MRadhakrishnan Gnanasambandam, Alicia Rivera, David H Vandorpe, et al.
Hemasphere|March 20, 2019
Controversies in the Treatment of Classical Hodgkin LymphomaDennis A Eichenauer, Marc André, Peter Johnson, et al.
Hemasphere|August 17, 2022
Molecular Cytogenetic Profiling Reveals Similarities and Differences Between Localized Nodal and Systemic Follicular LymphomasHeike Horn, Vindi Jurinovic, Ellen Leich, et al.
Hemasphere|March 6, 2023
In Humanized Sickle Cell Mice, Imatinib Protects Against Sickle Cell-Related InjuryEnrica Federti, Alessandro Matte, Antonio Recchiuti, et al.
Hemasphere|August 8, 2022
Five Percent Variant Allele Frequency Is a Reliable Reporting Threshold for TP53 Variants Detected by Next Generation Sequencing in Chronic Lymphocytic Leukemia in the Clinical SettingTatjana Pandzic, Claes Ladenvall, Marie Engvall, et al.
Hemasphere|March 2, 2023
Impact of Elotuzumab Plus Pomalidomide/Dexamethasone on Health-related Quality of Life for Patients With Relapsed/Refractory Multiple Myeloma: Final Data From the Phase 2 ELOQUENT-3 TrialKatja Weisel, Meletios A Dimopoulos, Jesús San-Miguel, et al.
Hemasphere|February 6, 2023
Resource: A Cellular Developmental Taxonomy of the Bone Marrow Mesenchymal Stem Cell Population in MicePaola Pisterzi, Lanpeng Chen, Claire van Dijk, et al.
Hemasphere|November 18, 2022
Acalabrutinib Versus Investigator's Choice in Relapsed/Refractory Chronic Lymphocytic Leukemia: Final ASCEND Trial ResultsPaolo Ghia, Andrzej Pluta, Małgorzata Wach, et al.
Pageof 65